Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Atezolizumab (Primary) ; Bempegaldesleukin (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms PROPEL
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 21 Dec 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Sep 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 26 Jun 2018 Planned number of patients changed from 60 to 75.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top